Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$15.43 USD
+0.47 (3.14%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.42 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DNLI 15.43 +0.47(3.14%)
Will DNLI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
Other News for DNLI
First Week of DNLI December 20th Options Trading
GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Denali Therapeutics price target lowered by $38 at UBS, here's why
Denali Therapeutics files to sell 29.29M shares of common stock for holders